AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04475692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional care
Description: Conventional care is the standard care offered to stroke patients in their respective settings. In this context it is guided by Royal College of Physicians (2016). For the purposes of this work, conventional care encompasses any rehabilitation or support services accessed by participants within the primary or secondary care setting, including private therapy services, charity-led exercise groups etc. Conventional care will not be specified in the context of this work, as it is complex in nature and varies between settings.
Study NCT03416361 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 4000IU Vitamin D3
Description: Chewable blackcurrant flavoured tablets (two per day)
Study NCT03416361 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4000IU Vitamin D3
Description: Chewable blackcurrant flavoured tablets (two per day)
Study NCT05573971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: with verbal encouragement
Description: Each athlete swam a maximal 200m freestyle trial in two different conditions: one trial with verbal encouragement and the other without verbal encouragement
Study NCT04755946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: adding one tablet of roflumilast 500 mcg to the standard ACEI (captopril) for diabetic nephropathy management
Study NCT04755946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05509868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBK_L1704 0.35mg
Description: The subject will receive PBK_L1704 0.35mg/ml by PCA
Study NCT05509868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBK_L1704 0.5mg
Description: The subject will receive PBK_L1704 0.5mg/ml by PCA
Study NCT05509868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subject will receive placebo by PCA
Study NCT04500847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtriva Capsule
Description: 200mg daily oral dose
Study NCT04500847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg daily oral dose
Study NCT06085300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sentence recast
Description: Recast therapy is a well-established treatment for grammar in children with DLD. In this treatment, the adult repeats the child's own utterance, altering it to include the taught structure. It yields consistent large effect sizes (Hedge's g = 0.7-1.0) when focused on a single target and provided at a high dose (10-20 hrs. of therapy at a rate of \~1 recast/minute or \~600-1000 recasts total) for both morphology and syntax .
Study NCT06478381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L218CAR19
Description: L218CAR19 is intravenously administered at three dose levels.
Study NCT06240910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamics
Description: Neuro dynamics involving Stretching and gliding of the Sciatic nerve (performing each exercise for 30 s at a slow and comfortable pace of 1 repetition per \~3-4 s. The participants rested for 60 s between each exercise.
Study NCT06240910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Aerobic exercise will involve warm-up by stretching and flexibility exercises for 5 minutes, Treadmill walking for 6 minutes, and Stationary bicycle for 6 minutes
Study NCT05152797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous tumor-infiltrating lymphocytes
Description: Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
Study NCT05319990 — intervention group
Intervention type: DRUG
Intervention: Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Description: PAH (Basic Pharma, Geleen, Netherlands) has been used to measure ERPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.
Study NCT05319990 — intervention group
Intervention type: DRUG
Intervention: Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Description: Iohexol (Omnipaque 300, GE Healthcare, Chicago, IL) is a nonionic, low osmolar contrast agent with a history of extensive use in Radiology practice (for contrast x-rays) that shares many qualities of an ideal GFR marker, like inulin, such as not being absorbed, metabolized, or secreted by the kidney.
Study NCT05723900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Castor oil
Description: Procedure :pulpotomy procedure and histological evaluation. A sample of sixty two primary teeth from thirty healthy cooperative children of both sexes who were between 7-9 years and referred to Pediatric Dentistry Department. Two sound teeth without pulpotomy procedure were extracted and subjected to histological procedures to examine the normal pulp tissue and tissue organization (Negative control). The pulpotomy procedure was performed in sixty primary teeth (by split mouth design).~group I treated with castor oil
Study NCT05723900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formocresol
Description: Group II treated with formocresol
Study NCT05479110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathy experience courses and case-base clinical reasoning
Description: Four 3-hour training sessions over 2 weeks, which included group instruction on empathy experience, clinical reasoning, and functional therapy case-oriented learning.
Study NCT05479110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: case studies
Description: active control: case studies(text)
Study NCT06002438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole egg powder
Description: 15g daily dose for 24 weeks
Study NCT06002438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn powder
Description: 15g daily dose for 24 weeks
Study NCT05845346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrotherapy-Transcutaneous Electrical Stimulation (TENS)
Description: Ten electrotherapy sessions lasting 30 minutes were carried out. Analgesic currents of the TENS type, placed in the cervical region.
Study NCT05845346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy
Description: Ten massage therapy sessions lasting 20 minutes each were carried out. Techniques such as superficial rubbing, deep rubbing, kneading and gliding pressure were performed on the cervical region.
Study NCT05845346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Ten stretching exercise sessions.The stretching exercise modality performed consisted of passive static stretching with a sequence of 30s-10s-30s-10s.
Study NCT05845346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischaemic Compression Technique
Description: Ten Ischaemic Compression Technique sessions. The execution of the technique is described as follows: after locating a painful point (trigger point), pressure is applied until pain is generated, then a position is sought where the pain disappears, the position of maximum comfort, which is maintained for 90 seconds (sec), after which time the patient is returned to the starting position in a passive manner.
Study NCT06002438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supercereal Plus
Description: Approximately 110 g per day (1.5 kg every 2 weeks) supplementary food to be provided for treatment of MAM for up to 6 weeks.
Study NCT06002438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supercereal Plus
Description: Approximately 110 g per day (1.5 kg every 2 weeks) supplementary food to be provided for treatment of MAM for up to 6 weeks.
Study NCT04096378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMBRace Intervention Group
Description: The EMBRace intervention will consist of five weekly sessions (weeks 2 - 6) that will be facilitated by EMBRace-trained therapists. Throughout the 8-week intervention, families will be scheduled for 2-hour blocks with sessions being administered to each parent and adolescent for 90 minutes (individually for 30 minutes, 15-minute break, and 45-minutes session with parent and adolescent together). The sessions will cover research-based types of Racial Socialization, including cultural pride, preparation for bias, and attentiveness and balance towards societal racism. Parents and youth will also learn and practice five literacy skills to process and manage the stress of racial encounters including the ability to recognize racial discrimination, accurately appraise the stress of self and others, reduce one's stress, engage instead of avoid, and finally resolve toward healthy outcomes.
Study NCT04096378 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EMBRace Waitlist Group
Description: The waitlist group will be asked to complete a pretest and posttest while the treatment group goes through the EMBRace intervention. During this time, the waitlist group will not have any additional requirements and will not be given any form of comparative treatments. Upon the completion of the treatment from the intervention group, the waitlist group will be consented for entry into the intervention arm of the study and will follow the procedures for the intervention group above.
Study NCT06002438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient sprinkles
Description: To be provided after completion of MAM supplementary feeding. Provides 1 RDA of 14 micronutrients.
Study NCT06002438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient sprinkles
Description: To be provided after completion of MAM supplementary feeding. Provides 1 RDA of 14 micronutrients.
Study NCT05337020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Each patient will be asked to fill in the questionnaire to assess their vision on telemedicine
Study NCT05463809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous Gastrocnemius plane block with ropivacaine
Description: After extubation, the patient was routinely monitored for his vital signs.The nerve block operation was performed by the same doctor: let the patient take the lateral decubitus position, use the ultrasonic high-frequency array probe under the popliteal socket to scan the sciatic nerve, move the probe down to find the tibial nerve and the common peroneal nerve, and then a single injection of 0.375% Ropivacaine 15milliliters was given into the common peroneal nerve, medial sural cutaneous nerve, and lateral sural cutaneous nerve. Then avoid common peroneal nerve, use the indwelling needle (16GA 3.25 IN), and put the catheter after saline expansion.
Study NCT05463809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone
Description: The patient was revived and received intravenous oxycodone titration according to the numerical rating scale (NRS) score, and was treated with no background dose of oxycodone patient-controlled intravenous analgesia (PCIA) pump for analgesia.
Study NCT06002438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine pyrimethamine
Description: Infants \< 12 months of age: 250/12.5mg SP at enrollment, week 6, week 12, week 18.~Infants >= 12 months of age: 500/25mg SP at enrollment, week 6, week 12, week 18.
Study NCT06002438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine pyrimethamine
Description: Infants \< 12 months of age: 250/12.5mg SP at enrollment, week 6, week 12, week 18.~Infants >= 12 months of age: 500/25mg SP at enrollment, week 6, week 12, week 18.
Study NCT04015830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroencephalography (EEG) and event related potentials (ERP)
Description: This is an exploratory study of EEG/ERP measures in older African American and Whites with HIV
Study NCT06136936 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CT-156-C-001
Description: CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.
Study NCT06136936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT-156-C-001
Description: CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.
Study NCT05491785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 600 µg
Description: Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, 3 cebranopadol 200 µg tablets and 2 cebranopadol placebo tablets
Study NCT05491785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 800 µg
Description: Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, 4 cebranopadol 200 µg tablets and 1 cebranopadol placebo tablet
Study NCT05491785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 1000 µg
Description: Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, and 5 cebranopadol 200 µg tablets
Study NCT05491785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 30 mg
Description: Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone 10 mg capsules, and 5 cebranopadol placebo tablets
Study NCT05491785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 60 mg
Description: Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone 20 mg capsules, and 5 cebranopadol placebo tablets
Study NCT05491785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, and 5 cebranopadol placebo tablets
Study NCT04895761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: DPX is a novel formulation that when combined with target antigens acts to activate T cells. It is a lipid-based formulation that creates a long lasting depot at the site of injection, forcing an active uptake by antigen presenting cells (APCs). APCs traffic to regional lymph nodes where naïve T cells are activated, inducing strong and sustained immune responses. All arms will receive DPX-Survivac on weeks 2 and 5.
Study NCT04895761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Aromatase inhibitor all arms will receive
Study NCT04895761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50mg
Description: oral chemotherapy used in the neoadjuvant setting for Arm C only
Study NCT04895761 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: XRT 10Gy x2
Description: Directed radiation at week 4 for Arm B only
Study NCT05831982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Person-centered strength training and nutrition intervention
Description: Focus on high intensity strength training and nutrition intervention with focus on energy and protein intake. Focus on social relations
Study NCT05831982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard training
Description: Training as usual when discharged with a rehabilitation plan.
Study NCT05437302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prism spectacle
Description: a prism is dispensed in prescription glasses
Study NCT05437302 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: prism spectacle
Description: a prism is dispensed in prescription glasses
Study NCT05977049 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Takotsubo Support Group
Description: Participants will undergo virtual group therapy/education. Participants will meet once every other week (at minimum), for 1 - 1.5 hours (on average). The frequency and/or length of the support group sessions may be adjusted according to participants' needs.
Study NCT06385067 — intervention group
Intervention type: DEVICE
Intervention: Biolimus Coated Coronary Artery Balloon Dilation Catheter
Description: Patients with Coronary Artery Disease will be treated with Biolimus Coated Coronary Artery Balloon Dilation Catheter
Study NCT05044052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emphasis on the Choosing Wisely Viral Prescription Pad
Description: We will investigate the effects of emphasizing the use of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing.
Study NCT05100641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-GBM-1
Description: Therapeutic autologous dendritic cell vaccine
Study NCT05100641 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous monocytes
Description: Autologous monocyte control
Study NCT05455957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: neuromuscular and vestibulo-ocular training
Study NCT05349240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C2 CryoBalloonTM Ablation System.
Description: Cryoablation is used to ablate the tissue under the cryogenic condition. The device is mainly used to destroy the unhealthy tissues.
Study NCT05089734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy (SG)
Description: Administered intravenously
Study NCT05089734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Administered intravenously
Study NCT05604378 — intervention group
Intervention type: PROCEDURE
Intervention: Gastrectomy
Description: All patients in our study underwent gastrectomy.
Study NCT02492932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Ultrasonography evaluation of the internal jugular vein.
Study NCT05730400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMAC loaded on bovine graft
Description: Bone marrow aspirate concentrate loaded on bovine graft for sinus floor augmentation
Study NCT05730400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bovine graft only
Description: Bovine graft only for sinus floor augmentation
Study NCT05417958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extremely thick blenderized tube feed
Description: Commercial blenderized tube feed, not diluted
Study NCT05417958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mildly thick blenderized tube feed
Description: Commercial blenderized tube feed, diluted with ingredients contained in blend
Study NCT04801628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Tecar
Description: Active Tecar
Study NCT04801628 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tecar
Description: Placebo Tecar
Study NCT05239520 — intervention group
Intervention type: OTHER
Intervention: 3D movement analysis with surface electromyography and ultrasound
Description: Single measurement session of 3D movement analysis with surface electromyography for upper limb movements and ultrasound measurements of upper muscles
Study NCT05508555 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hyperthermic intrathoracic chemotherapy
Description: application of chemotherapeutic agent intrathoracic under hyperthermic conditions
Study NCT04623645 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound technique
Description: evaluate the effect of ultrasound guided technique for block of internal branch of superior laryngeal nerve
Study NCT04623645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound technique
Description: evaluate the effect of ultrasound guided technique for block of internal branch of superior laryngeal nerve
Study NCT06054295 — intervention group
Intervention type: OTHER
Intervention: Biospecimen collection
Description: Collection of both blood and saliva samples from participants at the time of study enrollment
Study NCT06054295 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: The brief questionnaire will assess health history, demographics, environmental exposures, family history of cancer, and birth characteristics.
Study NCT05708391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Realgar-Indigo Naturalis Formulation
Description: Radiotherapy: after 4 courses of chemotherapy, radiotherapy was started 13 weeks later. The radiotherapy was performed by three-dimensional conformal intensity modulated radiation (IMRT) technique with a dose of 45-50.4 grey, and radiotherapy was performed 5 times per week for 5-6 weeks.~Oral administration of Realgar-Indigo naturalis formula from 1 week before radiotherapy to the whole radiotherapy period.~Dosage: oral, according to body weight, 3 times a day.Because the patient constitution is different, may first start from the half dose, within 3 days gradually increases the dose.In this study, the dosage of Realgar-Indigo naturalis formula (250mg per tablet) was determined according to the patient's weight stage.In each body weight segment, 60 mg/kg realgar-indigo naturalis formula were given according to the upper limit of body weight
Study NCT05708391 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy